Merck to present ataciept data at ACR/ARHP Annual Meeting

Merck KGaA will present the data on its investigational drug for the treatment of systemic lupus erythematosus ataciept at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting.
"There is a significant unmet medical need in systemic lupus erythematosus, with limited treatment options currently available for this debilitating disease," Luciano Rossetti, Merck KGaA's head of global research and development for the biopharma business, said. "The safety and efficacy data that will be presented at ACR/ARHP indicate that atacicept may play an important role as a potential new therapeutic option for patients with lupus. Our goal is to continue to advance innovation across our immunology pipeline that could make a meaningful difference for people living with lupus and other autoimmune diseases."
The data will be presented as a poster presentation. The ACR/ARHP Annual Meeting is scheduled for Friday through Wednesday in Washington, D.C.